Therapeutic potential of GW501516 and the role of Peroxisome proliferator-activated receptor β/δ and B-cell lymphoma 6 in inflammatory signaling in human pancreatic cancer cells  by Smith, Russell W. et al.
Contents lists available at ScienceDirect
Biochemistry and Biophysics Reports
journal homepage: www.elsevier.com/locate/bbrep
Therapeutic potential of GW501516 and the role of Peroxisome
proliferator-activated receptor β/δ and B-cell lymphoma 6 in inﬂammatory
signaling in human pancreatic cancer cells
Russell W. Smith, Jeﬀrey D. Coleman, Jerry T. Thompson, John P. Vanden Heuvel⁎
Department of Veterinary and Biomedical Sciences, Penn State University, University Park, PA, United States
A R T I C L E I N F O
Keywords:
Pparbeta
Bcl6
Pancreatic cancer
Inﬂammation
Macrophage
A B S T R A C T
Peroxisome proliferator-activated receptor β/δ (PPARβ/δ) is a member of the nuclear receptor superfamily and
a ligand-activated transcription factor that is involved in the regulation of the inﬂammatory response via
activation of anti-inﬂammatory target genes and ligand-induced disassociation with the transcriptional
repressor B-cell lymphoma 6 (BCL6). Chronic pancreatitis is considered to be a signiﬁcant etiological factor
for pancreatic cancer development, and a better understanding of the underlying mechanisms of the transition
between inﬂammation and carcinogenesis would help further elucidate chemopreventative options. The aim of
this study was to determine the role of PPARβ/δ and BCL6 in human pancreatic cancer of ductal origin, as well
as the therapeutic potential of PPARβ/δ agonist, GW501516. Over-expression of PPARβ/δ inhibited basal and
TNFα-induced Nfkb luciferase activity. GW501516-activated PPARβ/δ suppressed TNFα-induced Nfkb
reporter activity. RNAi knockdown of Pparb attenuated the GW501516 eﬀect on Nfkb luciferase, while
knockdown of Bcl6 enhanced TNFα-induced Nfkb activity. PPARβ/δ activation induced expression of several
anti-inﬂammatory genes in a dose-dependent manner, and GW501516 inhibited Mcp1 promoter-driven
luciferase in a BCL6-dependent manner. Several pro-inﬂammatory genes were suppressed in a BCL6-dependent
manner. Conditioned media from GW501516-treated pancreatic cancer cells suppressed pro-inﬂammatory
expression in THP-1 macrophages as well as reduced invasiveness across a basement membrane. These results
demonstrate that PPARβ/δ and BCL6 regulate anti-inﬂammatory signaling in human pancreatic cancer cells by
inhibiting NFκB and pro-inﬂammatory gene expression, and via induction of anti-inﬂammatory target genes.
Activation of PPARβ/δ may be a useful target in pancreatic cancer therapeutics.
1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease,
ranking as the fourth leading cause of cancer death with a 5-year
survival rate of 6% [1]. Behavioral risk factors associated with PDAC
include smoking and alcoholism, as well as metabolic disorders obesity
and diabetes mellitus. Treatment with gemcitabine and ﬂuorouracil
yielded 20% overall survival of PDAC to 6 months, to more current
regimes of nab-paclitaxel/gemcitabine and FOLFIRINOX yielding to
35–48% overall survival to 9–11 months [2]. Despite these regimes,
substantial improvements in therapeutics over the last 20 years have
been lacking, identiﬁcation of predictive biomarkers and therapeutic
targets are sorely needed.
There is a strong correlation between chronic pancreatitis and
pancreatic cancer development [3]. Molecular changes have been
observed during the transition from pancreatitis to pancreatic cancer
including mutations in inﬂammatory signaling molecules kirsten rat
sarcoma viral oncogene homolog (Kras) [4], serine protease inhibitor
kazal type 1 (Spink1) [5], cyclooxygenase-2 (Cox2), and nitric oxide
(No) [6,7]. Nuclear factor κ-light chain enhancer of activated B cells
(Nfkb1) is master regulator of inﬂammatory response and genes
involved in cell cycle, angiogenesis, and apoptosis [3]. Several pan-
creatic cancer cell lines and tissue have shown constitutive activation of
Nfkb1 [8,9]. Autocrine secretion of interleukin 1α (IL1α) activates
Nfkb1 in pancreatic cancer, concurrently, NFκB1 enhanced expression
of IL1α resulting in a positive feedback loop for this constitutive
activation [10]. NFκB1 signaling dysregulates downstream targets
involved in angiogenesis and metastasis such as vascular endothelial
growth factor (Vegf) and interleukin 8 (Il8) [11]. Clearly, NFκB1 plays
an essential role in cancer progression, and with the complexity of
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KRAS pathways making targeting therapeutics diﬃcult, NFκB1 be-
comes increasingly attractive candidate for treatment.
Evidence over the past 5-years has indicated Pparb is a feasible
target for chemoprevention [12], albeit not without controversy [13].
PPARβ/δ is a ubiquitously expressed ligand-activated transcription
factor that controls a number of cellular functions, and involved in
several metabolic disorders such as diabetes, obesity, and atherosclero-
sis [14–16]. It resides in the nucleus where it associated with
transcriptional suppressor BCL6 [17]. Through ligand activation of
PPARβ/δ, BCL6 dissociates from the complex and decreases inﬂam-
matory signaling by binding NFκB1 and STAT1 [18]. In addition,
PPARβ/δ dimerizes with retinoid x receptor (RXR) and directly
regulates expression of certain anti-inﬂammatory genes, such as
interleukin-1 receptor antagonist (Il1ra). The biological ramiﬁcations
of complex formation between PPARβ/δ and BCL6 are still being
elucidated, but both appear to be eﬀective repressors of inﬂammatory
markers in cell and animal models [19].
Little is known about the function of PPARβ/δ and BCL6 in the
pancreas or their roles in the etiology of PDAC. GW501516, a PPARβ/δ
agonist, attenuates inﬂammatory response in two diﬀerent pancreatitis
mouse models [20]. We sought to determine the role of PPARβ/δ and
BCL6 in the human ductal pancreas in regards to inﬂammation, and
the therapeutic potential of GW501516. Our observations show that
GW501516-mediated anti-inﬂammatory signaling via PPARβ/δ is
present in two pancreatic cancer cell lines- Mia PaCa-2 and BxPc-3.
PPARβ/δ suppresses Nfkb1 activity. Several pro-inﬂammatory markers
are inhibited by PPARβ/δ ligands in a BCL6-dependent manner.
Conditioned media experiments using RNAi to reduce expression of
PPARβ/δ and BCL6 in pancreatic cancer cells implicated both proteins
as regulators of inﬂammatory gene expression in a human macrophage
cell line, THP-1 cells, as well as aﬀect macrophage recruitment.
2. Materials and methods
2.1. Cells and reagents
Human pancreatic cancer cells, Mia PaCa-2 (COX2 negative, CRL-
1420) and BxPc-3 (COX2 positive, CRL-1687) were purchased from
ATCC (Manassas, VA) and cultured in high glucose DMEM containing
10% FBS. Human embryonic kidney 293 cells were cultured in DMEM
containing 10% FBS. THP-1 cells were cultured in RPMI 1640 media
supplemented with 10% FBS. All cell media contained 100U penicillin
and streptomycin, and cells were cultured in a humidiﬁed atmosphere
at 37 °C containing 5% CO2. All media components and FBS were
purchased from Gibco BRL/Life Technologies (Carlsbad, CA).
GW501516 used as a positive control for PPARβ/δ, and phorbol 12-
myristate 13-acetate (PMA), used to diﬀerentiate THP-1 cells, was
purchased from Sigma Chemical Company. The 2.8 kb mMcp1 (acces-
sion #U12470) promoter fragment cloned into the luciferase reporter
vector pGL3-basic (Promega) was provided by Dr. Ronald Evans (Salk
Institute for Biological Studies, La Jolla, CA). Transfection control
plasmids pRL-TK and pRLCMV were purchased from Promega
(Madison, WI). Recombinant htnfa was purchased from Invitrogen
(Carlsbad, CA) and reconstituted in nanopure water. MISSION©
Pparb, Bcl6, Il1ra, and scrambled non-targeting glycerol stocks were
purchased from Sigma-Aldrich. High Capacity cDNA Archive Kit and
ABI 7300 real-time PCR system were purchased from Applied
Biosystems (Foster City, CA). The pPACKH1 packaging plasmids and
the pCDNA3.1/Pparb-FLAG plasmid were provided by Dr. Curtis
Omiecinski (Penn State University). CytoSelect TM 96-well Invasion
Assay (basement membrane, ﬂuormetric format) was purchased from
Cell Biolabs, Inc. (San Diego, CA) and used according to manufacturer's
instructions.
2.2. NF-κB1 reporter assays
Mia PaCa-2 cells were seeded at 7.5×105 cells in 10 cm tissue
culture dishes. Cells were transiently transfected with 9 μg pNkfb1-
luciferase and 1 μg pRLCMV using LipofectAMINE (Invitrogen) re-
agent for 6 h and allowed to recover overnight. Cells were challenged
with the indicated treatments 24 h post-transfection, and Nfkb1-
luciferase activity was measured using Dual Luciferase Reporter
Assay (Promega) and normalized using control luciferase activity).
Cells were transfected with 5 μg Pparb-FLAG and 4 μg pNfkb1-
luciferase and 1 μg pRLCMV.
2.3. Isolation of total RNA and quantitative PCR
Total RNA was isolated from Mia PaCa-2 and BxPc-3 cells using
Tri-Reagent and the manufacturer's recommended protocol (Sigma).
Reverse transcription of 1 μg mRNA was done using the High Capacity
cDNA Archive Kit (Applied Biosystems, Foster City, CA). Primers for
quantitative Polymerase Chain Reaction (PCR) were designed based on
published sequences in GenBank and are shown in Table 1. The
housekeeping gene βactin was used to normalize all the tested genes.
The data shown are representative of three independent experiments
with triplicate samples.
2.4. Mcp1 reporter assay
Mia PaCa-2 cells transiently expressing non-targeting control, Bcl6
or Pparb shRNA were plated in 10 cm tissue culture dishes as
described. Cells were transiently transfected with 9 μg Mcp1-luciferase
and 1 μg pRLCMV for 6 h and allowed to recover overnight. Cells were
then challenged with the indicated treatments 24 h post-transfection
and Mcp1 promoter driven luciferase was assayed and corrected using
the internal transfection control pRLCMV.
2.5. Diﬀerentiation of THP-1 cells with PMA
Diﬀerentiation was achieved by resuspending THP-1 cells at a
density of 2×105 cells/mL in serum-free RPMI 1640 media supple-
Table 1
List of qPCR primers.
Gene Forward Primer Reverse Primer
bactin AACAAGAGGCCACACAAATAGG CAGATGTACAGGAATAGCCTCCG
Il1ra GGGAACTTTGCACCCAACAT TTGGCAGGTACTCAGCGAATG
Tgfb AGGTCCTTGCGGAAGTCAATG CTATTGCTTCAGCTCCACGGA
Sod1 TGCTTCCCCACACCTTCACTGGT ATGGCGACGAAGGCCGTGTG
Fgf21 CGCTGGCACAGGAACCTGGA ACCAGAGCCCCGAAAGTCTCCT
Mcp1 GGACGCATTTCCCCAGTACA CCGAGAACGAGATGTGGACA
Mcp3 ATGAGGTAGAGAAGGGAGGAGCAT CAAACTGGACAAGGAGATCTGTGC
Tnfa TGGATGTTCGTCCTCCTCACA ATCAATCGGCCCGACTATCTC
Il1b TCCTTAGTCCTCGGCCAAGAC GTGCCATGGTTTCTTGTGACC
Il6 CCGTCGAGGATGTACCGAATT GCCACTCACCTCTTCAGAACG
Cox2 CGGTGTTGAGCAGTTTTCTCC AAGTGCGATTGTACCCGGAC
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mented with 100 nM PMA for 24 h. Cells were then allowed to recover
in media containing 10% FBS for a further 24 h before use in
experiments.
2.6. Lentiviral RNAi
HEK-293 cells were grown to conﬂuency in 10 cm tissue culture
dishes under the conditions described above. The cells were then
transiently transfected with 4.6 μg of scrambled non-targeting control,
or Pparb, Bcl6, or Il1ra shRNA, as well as 2.4 μg each of pPACKH1
packaging plasmids, using LipofectAMINE 2000. Cells were transfected
for 6 h and allowed to recover overnight in normal media. Fresh media
was added the following morning, and pseudoviral supernatant was
generated for 72 h. Supernatant was then harvested and passed
through a 0.4 µm ﬁlter under sterile conditions. Polybrene (Millipore,
Billerica, MA) was then added to a ﬁnal concentration of 5 μg/mL and
the pseudoviral supernatant was then added directly to target cells for
6 h. Infected cells were allowed to recover overnight following the
addition of 6 mL complete media and knockdown of target genes was
assessed by qPCR 48 h post-infection. Knock down of indicated genes
were quantitated as described in a previous report [21].
2.7. Conditioned media experiments
Control or knockdown Mia PaCa-2 cells were plated at a density of
7.5×105 cells in 10 cm tissue culture plates. Following overnight
recovery the cells were challenged with 1 ng/mL TNFα with or without
500 nM GW501516 for 24 h. Conditioned media was collected and
centrifuged at 200×g at 20 °C for 10 min and any unused media was
stored at −80 °C. The same volume of normal media containing TNFα
with or without 500 nM GW501516 was prepared at the start of the
experiment and was used as control media. For gene expression assays,
undiluted conditioned media from control or knockdown Mia PaCa-2
cells were added directly to THP-1 cells and the cells were incubated for
24 h. Conditioned media was removed the following day and total RNA
was isolated and reverse transcribed as described above.
2.8. Cell migration assay
Experiments were performed using the CytoSelect TM 96-Well
Invasion Assay (Basement Membrane, Fluormetric Format) according
to the manufacturer's instructions. The basement membrane was
allowed to reach room temperature for 30 min, and rehydrated using
warm, serum-free DMEM. THP-1 cells were then seeded into each well
at a density of 2×106 cells/mL in serum-free media. Conditioned
media, as well as control media (DMEM containing 10% FBS, along
with TNFα with or without GW501516) was added to the feeder tray to
act as a chemoattractant and the entire apparatus was placed in an
incubator at 37 °C containing 5% CO2 for 24 h. CyQuant® GR dye/lysis
buﬀer solution was added to the invading cells following completion of
the assay and the resulting mixture was incubated at room temperature
for 20 mins. Invading cells were quantiﬁed by reading the ﬂuorescence
at 480 nm/520 nm. All measurements were performed in triplicate.
2.9. Statistical analysis
Quantitative data are presented as mean ± SEM. ANOVA with p-
value < 0.05 was used to determine whether diﬀerences among vari-
ables were signiﬁcant. Normality was checked using Anderson-Darling
test, and the general linear model, followed by the Tukey post hoc test
to analyze diﬀerences between treatments. All data analyses were
performed by MiniTAB Ver.14 (MiniTAB, State College, PA) or JMP
(SAS Institute, Cary, NC) and data were plotted by Prism 5.01
(GraphPad Software, San Diego, CA).
3. Results
3.1. Over-expression of Pparb inhibits Nfkb1 activity in Mia PaCa-2
cells
NFκB1 is a key regulator of inﬂammation [22] and is aﬀected by
PPARβ/δ via the p65 subunit [19]. To substantiate the anti-inﬂamma-
tory eﬀect of PPARβ/δ in human pancreatic cancer cells we sought to
evaluate the expression of the nuclear receptor on NFκB1 modulation.
Mia PaCa-2 cells were transfected with an Nfkb1 response element-
luciferase along with pcDNA3.1-Pparb-FLAG or empty vector. Over-
expression of Pparb reduced basal Nfkb1 activity. Treatment with
1 ng/mL tumor necrosis factor α (TNFα) induced Nfkb1 reporter
activity almost three-fold in control, this eﬀect was diminished in cells
over-expressing Pparb, even in the absence of ligand (Fig. 1A). This
indicates PPARβ/δ associates with and suppresses Nfkb1 activity in
human pancreatic cancer cells, suggesting an anti-inﬂammatory role
for PPARβ/δ in the pancreas.
3.2. Activation of PPARβ/δ reduces Nfkb1 activity in Mia PaCa-2
cells
To determine if Nfkb1 activity could be inﬂuenced by GW501516-
induced interaction with PPARβ/δ in human pancreatic cancer cells,
Mia PaCa-2 cells with Pparb or Bcl6 knocked down were transfected
with Nfkb1 response element-luciferase and treated with 1 ng/mL
TNFα in the presence or absence of 500 nM GW501516. In control
cells, GW501516 reduced both basal and TNFα-stimulated Nfkb1
luciferase activity, as well as slightly elevating basal activity though
Fig. 1. Eﬀects of Pparb expression and activation on Nfkb1 activity. A. Pparb expression
decreases basal and stimulated Nfkb1 activity. Mia PaCa-2 cells were seeded at 7.5×105/
mL in 10 cm culture dishes and transfected with 9 µg Nfkb1-luciferase and 1 µg pRLCMV
with or without pcDNA3.1-Pparb-FLAG for 24 h before challenge with TNFα or DMSO
control. Luciferase activity was assayed and corrected for transfection eﬃciency. *p <
0.05 B. BCL6 also plays a role in suppression of Nfkb1 activity. Mia PaCa-2 cells were
seeded at 7.5×105/mL in 10 cm dishes, infected with 4.6 µg of siRNA targeted against
Pparb, Bcl6, 2.4 µg pPACKH1 packaging plasmid for 6 h, and were transfected with
Nfkb1-luciferase. Cells were then challenged with the indicated treatments for 24 h and
luciferase activity was assayed and corrected for transfection eﬃciency. Diﬀerent letters
indicate a statistical diﬀerence at p < 0.05 using Tukey's multicomparison test.
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not signiﬁcant. TNFα-induced reporter activity was signiﬁcantly in-
creased when Bcl6 was knocked down, and GW501516 slightly lowered
this eﬀect. GW501516 treatment did not alter basal activity. Both basal
and TNFα-stimulated Nfkb1 activity were unaﬀected by GW501516
treatment when Pparb was knocked down (Fig. 1B). These results
indicate the observed reduction in Nfkb1 activity by GW501516 may
require both PPARβ/δ and its associated tumor suppressor BCL6.
3.3. GW501516 induces expression of anti-inﬂammatory genes in
Pparb-dependent manner
Activation of PPARβ/δ aﬀects anti-inﬂammatory genes in many cell
lines [22–24]. Mia PaCa-2 cells with Pparb or Bcl6 knocked down were
treated with 500 nM GW501516 or DMSO control, and mRNA
expression was assessed via qPCR. GW501516 increased expression
of interleukin-1 receptor agonist (Il1ra), transforming growth factor β
(Tgfb), superoxide dismutase-1 (Sod1), and ﬁbroblast growth factor 21
(Fgf21) in control and cells with Bcl6 knocked down. When Pparb was
knocked down, GW501516 treatment did not increase expression of
these target genes (Fig. 2). These results indicate the anti-inﬂammatory
eﬀects of GW501516 are mediated in part by the direct induction by
PPARβ/δ.
3.4. GW501516 inhibits expression of TNFα-induced pro-
inﬂammatory genes in Bcl6-dependent manner
The anti-inﬂammatory role of PPARβ/δ is mediated in part by
BCL6 [16,25], and involves several pro-inﬂammatory markers
[17,23,25]. Mia PaCa-2 cells expressing shRNA targeting Pparb or
Bcl6 along with monocyte chemoattractant protein-1 (Mcp1) promo-
ter-luciferase, were treated with 1 ng/mL TNFα to induce an inﬂam-
matory response. Mcp1 promoter-luciferase activity was increased in
control cells, and treatment with GW501516 reduced TNFα-induced
reporter activity to basal level. GW501516 reduced basal levels as well,
however, not to a signiﬁcant degree. TNFα-induced Mcp1 promoter-
luciferase activity was signiﬁcantly higher when Bcl6 was knocked
down, and GW501516 had no eﬀect. When Pparb was knocked down,
TNFα-stimulated Mcp1 promoter activity was reduced to approxi-
mately basal level with GW501516 having no eﬀect (Fig. 3A).
Reduction in Bcl6 appears to increase TNFα-induced activity of pro-
inﬂammatory Mcp1, whereas its release (via reduction in Pparb)
decreases reporter activity.
To see if this eﬀect was observed at the mRNA level, qPCR was
performed on Mcp1 and other known BCL6 target genes in cells under
the same conditions. GW501516 activation reduced mRNA in Mcp3,
Tnfa, and interleukin-1β (Il1b) in control infected cells, with minor
eﬀect on Mcp1. This aﬀect was not present when Bcl6 was knocked
down, and mRNA levels were increased with or without GW501516.
When Pparb was knocked down, mRNA levels were reduced despite
TNFα treatment (Fig. 3B). Taken together, these results conﬁrm the
anti-inﬂammatory eﬀect of GW501516 is mediated in part by BCL6.
3.5. GW501516 is anti-inﬂammatory in Cox2-positive human
pancreatic cancer cells
Since Mia PaCa-2 cells are reported to not express prostaglandin-
endoperoxide synthase 2 (Cox2) or interleukin 6 (Il6), it is important to
substantiate these results in a Cox2-positive cell line such as the
pancreatic cancer cells, BxPc-3. Cox2 plays a substantial role in
angiogenesis by the metabolism of arachidonic acid to factors that
contribute to angiogenesis signaling propagation [26]. This cell line
was transiently infected with Pparb, Bcl6, or scrambled control shRNA
and treated with TNFα with or without GW501516. GW501516
reduced the TNFα-induced expression of the Pparb target Il6 [27]
Fig. 2. GW501516 activated PPARβ/δ exerts anti-inﬂammatory eﬀects by increasing
expression of target genes. Mia PaCa-2 cells were seeded 7.5×105/mL in 10 cm dishes
and transiently infected with 4.6 µg of lentiviral-mediated shRNAs targeted against
Pparb or Bcl6 for 6 h, and 2.4 µg of pPACKH1 packaging plasmid. Cells were then
treated with 500 nM GW501516 or vehicle for 24 h. Gene expression was determined by
qPCR and expressed as fold induction following normalization to bactin. Diﬀerent letters
indicate a statistical diﬀerence at p < 0.05 using ANOVA and Tukey's post hoc multi-
comparison test.
Fig. 3. The transcriptional repressor BCL6 contributes to the anti-inﬂammatory actions
of GW501516 by suppressing target gene expression. A. Eﬀects of Pparb and Bcl6 knock-
down on TNFα-induced Mcp1 promoter driven luciferase. Mia PaCa-2 cells transiently
expressing 4.6 μg of the indicated shRNAs for 6 h and were transfected with 9 μg of
pGL3-Mcp1 promoter luciferase and treated with vehicle, 500 nM GW501516 or 1 ng/
mL TNFα with or without GW501516 for 24 h before luciferase activity was assayed. B.
Repression of TNFα-induced pro-inﬂammatory target genes by BCL6. Mia PaCa-2 cells
expressing the indicated shRNAs were treated with 1 ng/mL TNFα with or without
500 nM GW501516 for 24 h. Gene expression was determined by qPCR and expressed as
fold induction following normalization to bactin. Diﬀerent letters indicate a statistical
diﬀerence at p < 0.05 using ANOVA and Tukey's post hoc multicomparison test.
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though not signiﬁcant, and there was no signiﬁcant change in Cox2
mRNA. Knock down of Bcl6 signiﬁcantly increased inﬂammatory
response (Il6 and Cox2 expression) and was not signiﬁcantly aﬀected
by PPARβ/δ activation. Pparb knock down resulted in lower expression
of Il6 mRNA despite GW501516 (Fig. 4). These results substantiate in
BxPc-3 cells, GW501516 exerts its aﬀects via release of BCL6 from the
PPARβ/δ complex. Additionally, in our view, the therapeutic potential
of this pathway is not negatively altered by the absence of this
mechanism in Mia PaCa-2 cells.
3.6. GW501516 aﬀects crosstalk between human pancreatic cancer
cells and THP-1 macrophages
Tumor associated macrophages secrete molecules that aid in the
immunosuppressive microenvironment allowing malignancy and can-
cer progression by promoting angiogenesis and metastasis [28]. To
determine if conditioned media from Mia PaCa-2 cells could inﬂuence
gene expression in macrophages, Mia PaCa-2 cells were treated with
1 ng/mL TNFα with or without 500 nM of GW501516 after RNAi
knockdown of Pparb, Bcl6, Il1ra, and scrambled control for 48 h.
Conditioned media was added for 24 h to THP-1 cells diﬀerentiated to
macrophages. Accumulation of mRNA was examined via qPCR. Media
in absence of cells and media from cells not infected with the
pseudovirus were also used as controls along with media conditioned
by cells infected with scrambled non-targeting shRNA. Our results
show signiﬁcant GW501516-induced reduction of pro-inﬂammatory
markers within the THP-1 cells including Mcp1, Mcp3, Tnfa, Il1b, and
Il6, but not Cox2 in cells treated with control media and media from
the scrambled control shRNA group (Fig. 5). Conditioned media taken
from Bcl6-knock down cells treated with TNFα increased expression of
inﬂammatory markers in THP-1 cells, this inﬂammatory response was
decreased upon treating Mia PaCa-2 cells with GW501516. When
Pparb was knocked down in Mia PaCa-2 cells, Tnfa and Il6 production
in condition-media treated THP-1 cells was repressed (Fig. 5C & E).
Il1ra knock downs in Mia PaCa-2 did not signiﬁcantly alter gene
expression in THP-1 cells compared to control. Mcp1 and Mcp3 were
repressed in THP-1 macrophages following conditioned media from
GW501516-treated Il1ra knock downs suggesting Il1ra does not play a
signiﬁcant role in the crosstalk between pancreatic cancer cells and
macrophages.
3.7. GW501516 reduces THP-1 cell invasion in BCL6-dependent
manner
The BCL6 dissociation from PPARβ/δ by GW501516 activation
suppresses production of genes involved in macrophages chemotaxis,
therefore it was necessary to see if media conditioned by pancreatic
cancer cells under the same conditions would inﬂuence macrophage
migration across a basement membrane. THP-1 cells were seeded into
the upper chamber of an invasion plate in serum-free media, and
conditioned media from Mia PaCa-2 cells expressing the indicated
shRNAs treated with TNFα with or without GW501516 was used as the
chemoattractant. GW501516-treated Mia PaCa-2 conditioned media
reduced the amount of invading THP-1 cells, this was not seen when
Pparb was knocked down in the pancreatic cell line. Interestingly,
TNFα-induced invasion was increased 70% when Bcl6 was knocked
down in Mia PaCa-2. THP-1 migration was decreased 30% when Pparb
was knocked down in pancreatic cancer cells regardless of TNFα or
GW501516 (Fig. 6). BCL6 plays an integral part in the anti-inﬂamma-
tory eﬀects of GW501516, and seems to be the case for its anti-
migratory eﬀects as well. Though, PPARβ/δ is clearly anti-inﬂamma-
tory when activated by GW501516, it appears that when in the inactive
state, PPARβ/δ holds association with BCL6 preventing it from
exerting its eﬀects.
3.8. PPARβ/δ expression increases Mia PaCa-2 cell growth
Next, we sought to determine if increasing levels of PPARβ/δ
expression aﬀected cancer cell growth in a cell culture model. Mia
PaCa-2 cells transfected with pCDNA3.1- PPARβ/δ -FLAG or empty
vector control were treated with GW501516 or DMSO control and
allowed to grow for 72 h (Fig. 7). There was a 50% increase in cell
proliferation following transfection with 20 ng PPARβ/δ and a dou-
bling of cell number with 50 ng PPARβ/δ. This eﬀect was reversed by
the addition of GW501516 in cells transfected with 20–50 ng PPARβ/δ
plasmid. This further supports that sequestration of BCL6 by over-
expression of PPARβ/δ results in outcomes consistent with enhanced
growth and that agonist treatment partially restores BCL6 function.
4. Discussion
There is a growing amount of evidence [12] in support of the health
beneﬁts of PPARβ/δ agonists in particular in regard to protecting cells
from inﬂammation. Several studies have shown inﬂammation to be
correlated with pancreatic cancer progression [3,22,29–31]. This study
provides further evidence that GW501516-activated PPARβ/δ reduces
TNFα-induced Nfkb1 activity and inﬂammatory signaling via direct
induction of anti-inﬂammatory genes, as well as indirect inhibition of
pro-inﬂammatory genes by BCL6 dissociation in human pancreatic
cancer cells. Additionally, GW501516 treatment of Mia PaCa-2 cells
aﬀected gene expression in macrophages in manner consistent with
decreased invasive potential. This may indicate PPARβ/δ agonists
aﬀect crosstalk between cancer cells and tumor-associated macro-
phages. This is imperative because neoplastic response to therapy is
not solely based on the genomic anomalies the cancer cell contains, but
also the numerous factors within the tumor microenvironment.
Macrophages are key regulators of the tumor microenvironment,
angiogenesis, and metastasis [32]. Re-polarization of these immune
cells, in response to extracellular cues may provide an eﬀective
therapeutic option, although many intracellular signals that control
polarization are still being elucidated. Whether macrophage re-polar-
Fig. 4. Eﬀects of Pparb and Bcl6 knock down in Cox2-positive human pancreatic cancer
cells. BxPc-3 cells transiently expressing 4.6 μg of the indicated shRNAs were challenged
with 1 ng/mL TNFα with or without 500 nM GW501516 for 24 h. RNA was extracted by
standard tri-reagent protocol. Gene expression was determined by qPCR and expressed
as fold induction following normalization to βactin. Diﬀerent letters indicate a statistical
diﬀerence at p < 0.05 using ANOVA and Tukey's post hoc multicomparison test.
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ization or reduction in macrophage population would be a more
eﬀective strategy based on tissue type and disease progression is being
investigated [33]. Macrophage deletion in breast [34], and Ewing's
sarcoma animal models have resulted in decrease tumor incidence
[35].
Pparb over-expression signiﬁcantly reduced basal and TNFα-in-
duced Nfkb1 reporter activity in a process likely mediated, in part, by
direct interaction with the p65 subunit as described previously [19].
GW501516 reduced Nfkb1 activity in control cells, but not when Pparb
or Bcl6 were knocked down, indicating the potential repressive
mechanism is dependent on both proteins. The p65 subunit of
NFκB1 is constitutively active in human pancreatic cancer cells [36],
and is implicated in the progression of pancreatic tumorigenesis [37].
Inhibition of Nfkb1 via PPARβ/δ has already been established in
endothelial cells and cardiomyocytes [38], but GW501516-mediated
inhibition in the pancreas occurred directly or indirectly via ERK1/2
map kinase phosphorylation as in adipocytes [27] has yet to be
determined. TNFα-induced Nfkb1 activity was signiﬁcantly increased
when Bcl6 was knocked down indicating Bcl6 does participate in
regulation of Nfkb1 activity. GW501516 may provide a useful ther-
apeutic strategy by attenuation of Nfkb1 by both PPARβ/δ and BCL6.
GW501516 also increased mRNA expression of anti-inﬂammatory
Fig. 5. Conditioned media from Mia PaCa-2 cells inﬂuences gene expression in diﬀerentiated THP-1 cells. Mia PaCa-2 cells were infected with 4.6 μg of the indicated shRNAs for 6 h,
recovered overnight, and treated with 1 ng/mL of TNFα with or without 500 nM GW501516 to condition the media for 48 h. Equal aliquots of conditioned media or control media
(media placed in a 10 cm dish without cells) were then added to PMA-diﬀerentiated THP-1 cells. Gene expression of the pro-inﬂammatoryMcp1 (A),Mcp3 (B), Tnfa (C), IL1ra (D), Il6
(E) and Cox2 (F) was determined by qPCR and expressed as fold induction following normalization to bactin. Diﬀerent letters indicate a statistical diﬀerence at p < 0.05 using Tukey's
multicomparison test.
Fig. 6. Mia PaCa-2 GW501516-conditioned media reduces the percentage of invading
THP-1 cells across a basement membrane. Media was conditioned by Mia PaCa-2 cells
expressing the indicated shRNAs and treated with TNFα with or without 500 nM
GW501516 for 48 h. Conditioned media was used as a chemoattractant for THP-1 cells.
THP-1 monocytes were allowed to migrate across the membrane for 24 h and relative
invasion was quantiﬁed using the CytoSelect 96-well cell invasion assay with ﬂuormetric
readings at 480 nm/520 nm. Diﬀerent letters indicate a statistical diﬀerence at p < 0.05
using Tukey's multicomparison test.
Fig. 7. PPARβ/δ expression increases Mia PaCa-2 cell growth and is ameliorated by
GW501516. Mia PaCa-2 cells were seeded in 96-well plates at 2×103 per well, treated
with 250 nM GW501516 or DMSO control, and allowed to grow for approximately 72 h.
Plates were analyzed for luminescence using a GloMax microplate luminometer set at
750 nm. Diﬀerent letters indicate a statistical diﬀerence at P < 0.05 using Tukey's
multicomparison test.
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markers- IL1Ra, TGFβ, SOD1, and FGF21. IL1Ra, an IL1β antagonist
[39], and TGFβ are both PPARβ/δ targets that contribute to the
inhibition of IL1β-induced cell migration. SOD1 was also induced, a
gene involved in oxidative stress and contains a functional Peroxisome
Proliferator Response Element (PPRE) in its 5′-ﬂanking region [23].
FGF21 is regulated by PPAR-dependent pathways in mice, and protects
pancreatic acini from damage via inﬂammation [40]. We demonstrate
here the anti-inﬂammatory properties of GW501516 in human pan-
creatic cancer is in part through activation of PPARβ/δ and that the
reduction in inﬂammatory response is in part through direct induction
of anti-inﬂammatory genes by PPARβ/δ.
GW501516 also increased mRNA expression of anti-inﬂammatory
markers- Il1ra, Tgfb, Sod1, and Fgf21. IL1Ra, an IL1β antagonist [39],
and TGFβ are both PPARβ/δ targets that contribute to the inhibition of
Il1β-induced cell migration in vascular smooth muscle cells [41]. Sod1
was also induced, a gene involved in oxidative stress and contains a
functional peroxisome proliferator response element (PPRE) in its 5′
ﬂanking region [23]. Fgf21 is regulated by PPAR-dependent pathways
in mice, and protects pancreatic acini from damage via inﬂammation
[40]. We demonstrate here the anti-inﬂammatory properties of
GW501516 in human pancreatic cancer is in part through activation
of PPARβ/δ and that the reduction in inﬂammatory response is in part
through direct induction of anti-inﬂammatory genes by PPARβ/δ.
Unlike PPARβ/δ, the closely related subtypes PPARα and PPARγ
lack aﬃnity for BCL6. Since dissociation of BCL6 from the PPARβ/δ
complex is largely responsible for the anti-inﬂammatory properties of
PPARβ/δ ligands in mouse macrophages [25], and in animal models
[16], this is a unique mode of action available to this receptor. Our data
shows this Bcl6 pathway is active in the human pancreas and is
dependent on activation of PPARβ/δ. Conversely, PPARβ/δ in the
inactive state sequesters BCL6, preventing its anti-inﬂammatory prop-
erties. This may indicate increased expression of Pparb, despite being
anti-inﬂammatory when activated, may play a pro-inﬂammatory role in
the unliganded state as well. L-165041, a PPARβ/δ activator, has been
found in cardiomyocytes to increase free BCL6 by not only dissociating
BCL6 from PPARβ/δ, but also increasing expression by JNK/p38/Akt
activation [42].
Inhibition of Vegf reduced macrophage inﬁltration and cancer
growth in an orthotopic mouse model of pancreatic cancer [43].
Conditioned media from TNFα-treated Mia PaCa-2 cells eﬀected gene
expression in THP-1 cells, inducing pro-inﬂammatory gene expression
including Vegf. Conditioned media from cells treated with GW501516
signiﬁcantly lowered mRNA expression of pro-inﬂammatory markers
in macrophages. Utilizing RNAi in this study has shown PPARβ/δ and
BCL6 may play a role in this pancreatic cancer-macrophage crosstalk.
GW501516 reduced macrophage inﬁltration by 30% in control cells,
and a reduction in BCL6 protein showed a 70% increase in invasion
clarifying the importance of this transcriptional suppressor in macro-
phage migration. More importantly, however, was the reduction in
PPARβ/δ protein lowered invading macrophages compared to control.
Further experimentation is required to fully elucidate the role PPARβ/δ
and BCL6 play in the exocrine pancreas, but this data is in support of
the anti-inﬂammatory properties of this pathway and potential for
ameliorating cancer:macrophage crosstalk in the human pancreas.
Appendix A. Transparency document
Transparency document associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.bbrep.2016.10.014.
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